Meeting
2023 ASCO Genitourinary Cancers Symposium
Societal benefits of surrogate outcomes to support reimbursement decisions: The case of prostate cancer.
Authors
Rafael de Feria Cardet
CHERE, University of Technology Sydney, Sydney, NSW, Australia
Rafael de Feria Cardet , Ian D. Davis , Marion Haas , Tracey-Lea Laba , Stephen Goodall , Richard De Abreu Lourenço
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 372)
DOI
10.1200/JCO.2023.41.6_suppl.372
Abstract #
372
Poster Bd #
N10
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Addition of abiraterone to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Model to estimate long-term survival, quality-adjusted survival, and cost-effectiveness.
First Author: Caroline Sarah Clarke
Poster
2018 ASCO Annual Meeting
Network metanalysis and cost-effectiveness of abiraterone, docetaxel or placebo plus androgen deprivation therapy (ADT) for hormone-sensitive advanced prostate cancer.
First Author: Pedro Nazareth Aguiar
First Author: Elena Castro
Poster
2024 ASCO Genitourinary Cancers Symposium
Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial.
First Author: Neal D. Shore